Nkarta, Inc. Common Stock NKTX

$1.25 +3.31% at last close
Market Cap$86.67 million
P/E Ratio—
Div Yield—
Volume1.04M
52-Week Range $1.10$3.72

Analyst Ratings

Consensus
Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
Avg. Price Target
$11.25 (+800.0% upside)

Full NKTX forecast & analyst actions →

Key Stats

Today's Range
$1.15 – $1.28
50-Day Range
$1.10 – $3.20
52-Week Range
$1.10 – $3.72
Volume
1.04 million shs
Average Volume
1.46 million shs
Market Cap
$86.67 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.09%
Days to Cover
1.00

About Nkarta, Inc. Common Stock

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
103
Exchange
XNAS
Listed
2020-07-10

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.